Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
14.09
-1.22 (-7.97%)
Dec 12, 2025, 4:00 PM EST - Market closed
Company Description
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates.
Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations.
The company is headquartered in Waltham, Massachusetts.
Crescent Biopharma, Inc.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Joshua Brumm |
Contact Details
Address: 300 Fifth Avenue Waltham, Massachusetts 02451 United States | |
| Phone | 617-430-5595 |
| Website | crescentbiopharma.com |
Stock Details
| Ticker Symbol | CBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001124105 |
| CUSIP Number | 14888D208 |
| ISIN Number | KYG2545C1042 |
| Employer ID | 56-2020050 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joshua T. Brumm | Chief Executive Officer and Director |
| Dr. Jonathan McNeill M.D. | President and Chief Operating Officer |
| Richard William Scalzo M.B.A. | Chief Financial Officer |
| Ryan Lynch | Senior Vice President of Finance, Treasurer and Chief Accounting Officer |
| Dr. Wenjie Cheng Ph.D. | Senior Vice President of Technical Operations |
| Dr. Jan Pinkas Ph.D. | Chief Scientific Officer |
| Amy Reilly | Chief Communications Officer |
| Christopher Doughty | Chief Business Officer |
| Dr. Ellie Im M.D. | Chief Medical Officer |
| Tanya Sengupta | Executive Vice President and Chief of Strategy and Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2025 | 144 | Filing |
| Nov 7, 2025 | 10-Q | Quarterly Report |
| Nov 7, 2025 | 8-K | Current Report |
| Sep 10, 2025 | 8-K | Current Report |
| Aug 22, 2025 | 8-K | Current Report |
| Aug 11, 2025 | 10-Q | Quarterly Report |
| Aug 11, 2025 | 8-K | Current Report |
| Jun 6, 2025 | 8-K | Current Report |
| May 23, 2025 | 8-K | Current Report |
| May 23, 2025 | 424B5 | Filing |